Latest clinical evidence of maintenance therapy in ovarian cancer
CS Walsh - Current Opinion in Obstetrics and Gynecology, 2020 - journals.lww.com
Latest clinical evidence of maintenance therapy in ovarian c... : Current Opinion in Obstetrics
and Gynecology Latest clinical evidence of maintenance therapy in ovarian cancer : Current …
and Gynecology Latest clinical evidence of maintenance therapy in ovarian cancer : Current …
Frontline maintenance treatment for ovarian cancer
O Elyashiv, YNS Wong, JA Ledermann - Current Oncology Reports, 2021 - Springer
Abstract Purpose of Review Advanced epithelial ovarian cancer remains the most lethal
gynaecological cancer. Most patients with advanced disease will relapse within 3 years after …
gynaecological cancer. Most patients with advanced disease will relapse within 3 years after …
Maintenance chemotherapy in the management of epithelial ovarian cancer
M Markman - Cancer and Metastasis Reviews, 2015 - Springer
The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful
survival endpoint (overall, symptom-free, progression-free) while at the same time not …
survival endpoint (overall, symptom-free, progression-free) while at the same time not …
[HTML][HTML] Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?
P DiSilvestro, AA Secord - Cancer Treatment Reviews, 2018 - Elsevier
Approximately 1% of women in the United States will be diagnosed with epithelial ovarian
cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage …
cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage …
Front-line maintenance therapy in advanced ovarian cancer—current advances and perspectives
T Reverdy, C Sajous, J Péron, O Glehen, N Bakrin… - Cancers, 2020 - mdpi.com
Ovarian tumor is the gynecological cancer associated with the highest mortality. Most
diseases are diagnosed at an advanced stage, which impairs the chances of prolonged …
diseases are diagnosed at an advanced stage, which impairs the chances of prolonged …
Wanna get away? Maintenance treatments and chemotherapy holidays in gynecologic cancers
A Madariaga, GJS Rustin, RJ Buckanovich… - American Society of …, 2019 - ascopubs.org
Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically
approximately 70% of patients with a complete clinical response to surgery and adjuvant …
approximately 70% of patients with a complete clinical response to surgery and adjuvant …
Recurrent ovarian cancer: when and how to treat
Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most
patients will ultimately develop recurrent disease. The benefits of detection and early …
patients will ultimately develop recurrent disease. The benefits of detection and early …
Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives
V Salutari, E Giudice, D Lorusso - Current Opinion in Obstetrics …, 2024 - journals.lww.com
These data led American and European Treatment guidelines to include bevacizumab,
olaparib, niraparib, rucaparib, and combination bevacizumab-olaparib as maintenance …
olaparib, niraparib, rucaparib, and combination bevacizumab-olaparib as maintenance …
A review of the current evidence for maintenance therapy in ovarian cancer
T Foster, TM Brown, J Chang, HD Menssen… - Gynecologic …, 2009 - Elsevier
OBJECTIVES: Ovarian cancer (OC) typically is diagnosed at advanced stages, in which the
primary goal of therapy is to prolong progression-free survival (PFS) and overall survival …
primary goal of therapy is to prolong progression-free survival (PFS) and overall survival …
Maintenance therapy in ovarian cancer
S Khalique, JM Hook… - Current Opinion in …, 2014 - journals.lww.com
The principle of using molecular targeted therapy to prolong the control of ovarian cancer
has been clearly demonstrated. The greatest effect is on prolongation of PFS and, by adding …
has been clearly demonstrated. The greatest effect is on prolongation of PFS and, by adding …